Study Design The preliminary efficacy and safety of fingolimod was evaluated in a Phase II, 6-month, proof-of-concept study that randomized 281 patients to receive fingolimod 1.25 mg or 5.0 mg versus ...

VANCOUVER — Fingolimod (Gilenya, Novartis) was better tolerated than dimethyl fumarate (Tecfidera, Biogen) in a 2-year comparison of the oral multiple sclerosis (MS) drugs. Patients receiving dimethyl ...

Fingolimod therapy can cause persistent heart rate slowing in patients with preexisting parasympathetic predominance due to autonomic dysfunction. A study of 34 RRMS patients found prolonged ...

Learn everything you need to know about Fingolimod-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Fingolimod is an oral immunomodulating drug used in the management of relapsing-remitting multiple sclerosis (RRMS). We aim to review the published literature on ocular manifestations of fingolimod ...

A new study indicates that rituximab is more effective than fingolimod for preventing relapses in patients with highly active multiple sclerosis switching from treatment with natalizumab. The study ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of fingolimod, having considered evidence on the nature of highly active relapsing–remitting multiple ...

A recent study sought to compare several available oral immunotherapies for the treatment of relapsing-remitting multiple sclerosis (MS). A recent study sought to compare several available oral ...

Relapsing-remitting multiple sclerosis (MS) is commonly treated with parenteral drugs that can lead to adverse events and poor adherence. Three phase 3 randomized trials evaluated the efficacy and ...

Tascenso ODT is a sphingosine 1-phosphate receptor modulator. Tascenso ODT ®, an orally disintegrating formulation of fingolimod, has been made available by Cycle Pharmaceuticals. The product is ...

Fingolimod (Gilenya, Novartis Pharmaceuticals UK) is a sphingosine-1-phosphate receptor modulator that prevents lymphocytes from crossing the blood–brain barrier and causing damage to nerve cells in ...